Smoking, estradiol metabolism and hormone replacement therapy

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 1, 2003, Pages 1-11

  Mueck, Alfred O ^a,b   Seeger, Harald ^a  

^a University Women's Hospital   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

CAS 50 28 2; Estradiol, clinical studies, effect of smoking; Hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; PROGESTERONE; TRISEQUENS;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; FIRST PASS EFFECT; HORMONE METABOLISM; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIPID METABOLISM; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SMOKING;

EID: 0037244696     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297063     Document Type: Review

References (71)

1. Keil, U., Prevention of classical risk factors. A public health and healthy policy task. Arzneim.-Forsch./Drug Res. 40, 288 (1990)
2. American Cancer Society. Cancer, facts and figures, pp. 1-28, Amercian Cancer Society, Atlanta, Georgia (1993)
3. Statistisches Bundesamt Wiesbaden, Mitteilungen DMW 119, 324 (1994)
4. Surgeon General's Report on Women and Smoking. Roper ASW Press Release, Miami (USA); Nov 1 (2001)
5. Hu, F. B., Stampfer, M. J., Manson, J. E. et al., Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N. Engl. J. Med. 343, 530 (2000)
6. Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA 288, 312 (2002)
7. Cramer, D. W., Huijuan, X., Predicting age at menopause. Maturitas 23, 319 (1996)
8. Friedman, A. J., Ravnikar, V. A., Barbieri, R. I., Serum steroid hormone profiles in postmenopausal smokers and non-smokers. Fertil. Steril. 47, 398 (1987)
9. Key, T. J. A., Pike, M. C., Brown, J. B. et al., Cigarette smoking and urinary oestrogen excretion in premenopausal and postmenopausal women. Br. J. Cancer 74, 1313 (1996)
10. MacMahon B., Trichopoulos D., Cole P. et al., Cigarette smoking and urinary estrogens. N. Engl. J. Med. 307, 1062 (1982)
11. Michnovicz, J. J., Hershcopf, R. J., Naganuma, H. et al., Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N. Engl. J. Med. 315, 1305 (1986)
12. Michnovicz, J. J., Naganuma, H., Hershcopf, R. J. et al., Increased urinary catechol estrogen excretion in female smokers. Steroids 52, 69 (1988)
13. Greenberg, G., Thompson, S. G., Meade, T. W., Relation between cigarette smoking and use of hormonal replacement therapy for menopausal symptoms. J. Epidemiol. Comm. Health 41, 26 (1987)
14. Hammond, E. C., Smoking in relation to physical complaints. Arch. Environ. Health 3, 28 (1961)
15. Craig, W. Y., Palomaki, G. E., Haddow, J. E., Cigarette smoking and serum lipid and lipoprotein concentration: an analysis of published data. Br. Med. J. 298, 784 (1989)
16. Jensen, J., Christiansen, C., Effects of smoking on serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy. Am. J. Obstet. Gynecol. 159, 820 (1988)
17. Krauss, R. M., Periman, J. A., Ray, R. et al., Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women. Am. J. Obstet. Gynecol. 158, 1606 (1988)
18. Aloia, J. G., Cohn, S. H., Vaswani, A. et al., Risk factors for menopausal osteoporosis. Am. J. Med. 78, 95 (1985)
19. Baron, J. A., Farahmand, B. Y., Weiderpass, E. et al. Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch. Intern. Med. 161, 983 (2001)
20. Paganini-Hill, A., Ross, R. K., Gerkins, V. R. et al., Menopausal estrogen therapy and hip fractures. Ann. Intern. Med. 95, 28 (1981)
21. Tuppurainen, M., Honkanen, R., Kröger, H. et al., Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women - results of the Kuopio Osteoporosis Risk Factor and Prevention Study. Maturitas 17, 89 (1993)
22. Jensen, G. F., Osteoporosis of the slender smoker revisited by epidemiologic approach. Eur. J. Clin. Invest. 16, 239 (1986)
23. Wack, J. T., Rodin, J., Smoking and ist effects on body weight and the systems of caloric regulation. Am. J. Clin. Natr. 35, 366 (1982)
24. Felson, D. T., Zhang, Y., Hannan, M. T. et al., The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329, 1141 (1993)
25. Jensen, J., Christiansen, C., Rodbror, P., Cigarette smoking, serum estrogen, and bone loss during hormone replacement therapy early after menopause. N. Engl. J. Med. 313, 973 (1985)
26. Kiel, D. P., Baron, J. A., Anderson, J. J. et al., Smoking eliminates the protective effect of oral estrogen on the risk for hip fracture among women. Ann. Internal. Med. 116, 716 (1992)
27. Komulainen, M., Kroeger, H., Tuppurainen, M. T. et al., Oral estradiol - identification of early postmenopausal women with no bone response to HRT. Osteoporosis Int. 11, 211 (2000)
28. Leino, A., Impivaara, O., Kaitsaari, M., Effects of HRT on bone in women smokers and alcohol consumers. J. Bone Miner. Res. 12 (Suppl. 1), S355 (1997)
29. Nisker, J. A., Marunlic, M. A., Cigarette smoking and bone loss during hormone replacement after menopause (Letter). N. Engl. J. Med. 314, 854 (1986)
30. Valk-de Roo, G. W., Netelenbos, J. C., Peters-Muller, I. R. A. et al., Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover. Maturitas 28, 153 (1997)
31. Cubrilo-Turek, M., Stavljenic-Rukavina, A., Turek, S. et al., The usefulness of biochemical markers in predicting the response of hormone replacement therapy in perimenopausal smoking healthy women. Coll. Antropol. 23, 195 (1999)
32. Hulley, S., Grady, D., Bush, T. et al., Randomized trial for estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280, 605 (1998)
33. Franks, A. L., Kendricks, J. S., Tyler, C. W., Postmenopausal smoking, estrogen replacement therapy, and the risk of endometrial cancer. Am. J. Obstet. Gynecol. 156, 20 (1987)
34. Mueck, A. O., Römer, Th., in: Stoffwechsel und Hormonsubstitution, A. O. Mueck, Th. Römer (Eds.), pp. 159-193. Thieme Verlag, Stuttgart, New York (2002)
35. Mueck, A.O., HRT und kardiovaskuläre Erkrankungen - Aktuelle Stellungnahme. Frauenarzt 42, 744 (2001)
36. Craig, W. Y., Palomaki, G. E., Haddow, J. E., Cigarette smoking and serum lipid and lipoprotein concentration: an analysis of published data. Br. Med. J. 298, 784 (1989)
37. Criqui, M. H., Wallace, R. B., Heiss, G., Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study. Circulation 62 (Suppl IV), 70 (1980)
38. Teede, H. J., Liang, Y. L., Shiel, L. M. et al., Hormone replacement therapy in postmenopausal women protects against smoking-induced changes in vascular function and function. J. Am. Coll. Cardiol. 34, 131 (1999)
39. Girdler, S. S., Hinderliter, A. L., West, S. G. et al., Postmenopausal smokers show reduced hemodynamic benefit from oral hormone replacement. Am. J. Cardiology 86, 590 (2000)
40. Ylikorkala, O., Cacciatore, B., Paakari, I. et al., The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil. Steril. 69, 883 (1998)
41. Geisler, J., Omsjo, I. H., Helle, S. I. et al. Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. J. Endocrinology 162, 265 (1999)
42. Wilson, P. W. F., Garrison, R. J., Castelli, W. P., Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N. Engl. J. Med. 313, 1038 (1985)
43. Henderson, B. E., Paganini-Hill, A., Ross, R. K., Estrogen replacement therapy and protection from acute myocardial infarction. Am. J. Obstet. Gynecol. 159, 312 (1988)
44. Mann, R. D., Lis, Y., Chukwujindu, J. et al., A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women. J. Clin. Epidmiol. 47, 307 (1994)
45. Cassidenti, D. L., Vijod, A. G., Vijod, M. A. et al., Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am. J. Obstet. Gynecol. 163, 1953 (1990)
46. Cramer, D. W., Harlow, B. L., Huijuan, X. et al., Cross-sectional and case-controlled analyses of the association between smoking and early menopause. Maturitas 22, 79 (1995)
47. Grainge, M. J., Coupland, C. A., Cliffe, S. J. et al., Cigarette somoking, alcohol and caffein consumption, and bone mineral densitiy in postmenopausal women. The Nottingham EPIC Study Group. Osteoporosis Int. 8, 355 (1998)
48. Lippert, T. H., Seeger, H., Mueck, A. O., Pharmacology and toxicology of different estrogens. Gynecol. Endocrinol. 15 (Suppl 4), 26 (2001)
49. Lippert, T. H., Seeger, H., Mueck, A. O., in: Handbook of Experimental Pharmacology, Vol. 135/I: Estrogens and anti-estrogens, M. Oettel M, E. Schillinger E (eds.), pp. 243-271. Springer Heidelberg, New York (1999)
50. Mueck, A. O., Lippert, T. H., Hormonsubstitution in der Peri- und Postmenopause bei gleichzeitigem Vorliegen internistischer Erkrankungen. Münch. Med. Wochenschr. 139, 495 (1997)
51. Barbieri, R. L., Gochberg, J., Ryan, K. J., Nicotine, cotinine, and anabasine inhibit aromatase in human trophoblast in vitro. J. Clin. Invest. 77, 1727 (1986)
52. Barbieri, R. L., McShane, J., Ryan, K. J., Constituents of cigarette smoking inhibit human granulosa cell aromatase. Fertil. Steril. 46, 232 (1984)
53. McMurtry, R. J., Hagerman, D. D., Carbon monoxide inhibition of progesterone hydroxylation and sind chain cleavage catalyzed by rat testis microsomes. Steroid Lipid Res. 3, 8 (1972)
54. Fishman, J., Role of 2-hydroxyestrone in estrogen metabolism. J. Clin. Endocrinol. Metab. 23, 207 (1963)
55. Jusko, W. J., Role of tobacco smoking in pharmacokinetics. J. Pharmacokinet. Biopharm. 6, 7-39 (1978)
56. Lippert, T. H., Seeger, H., Mueck, A. O., The impact of estrogen metabolites on carcinogenesis. Steroids 65, 357 (2000)
57. Mattison, D. R., Morphology of oocyte and follicle destruction by polycyclic aromatic hydrocarbons in mice. Toxicol. Appl. Pharmacol. 53, 249 (1980)
58. Lippert, C., Seeger, H., Mueck, A. O. et al., The effect of endogenous estradiol metabolites on the proliferation of vascular endothelial cells. Life Sciences 67, 1653 (2000)
59. Lippert, T. H., Seeger, H., Mueck, A. O., Estrogens and the cardiovascular system: Role of estradiol metabolites in hormone replacement therapy. Climacteric 1, 296 (1999)
60. Mueck, A. O., Seeger, H., Lippert, C. et al., Angiogenetic and antiangiogenetic effects of estradiol and of its metabolites. J. Clin. Basic Cardiology 4, 153 (2001)
61. Seeger, H., Mueck, A. O., Lippert, T. H., Effect of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sciences 65, 167 (1999)
62. Seeger, H., Mueck, A. O., Lippert, T. H., The antiproliferative effect of 17β-estradiol metabolites on human coronary artery smooth muscle cells. Med. Sci. Res. 26, 481 (1998)
63. Seeger, H., Mueck, A. O., Lippert, T. H., The inhibitory effect of endogenous estrogen metabolites on copper-mediated oxidation of LDL. Int. J. Clin. Pharm. Therapeutics 36, 383 (1998)
64. Yager, J. D., Liehr, J. G., Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 36, 203 (1996)
65. Berstein, L. M., Tsyrlina, E. V., Kolesnik, O. S. et al., Catecholestrogens excretion in smoking and non-smoking postmenopausal women receiving estrogen replacement therapy. J. Steroid Biochem. Mol. Biol. 72, 143 (2000)
66. Thompson, P. A., Ambrosone, C., Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J. Natl. Cancer. Inst. Monogr. 27, 125 (2000)
67. Mueck, A. O., Brucker, C., Teichmann, A. T., für SiKuS (Arbeitsgemeinschaft "Steroide in Kontrazeption und Substitution" des Berufsverbandes der Frauenärzte, BVF), Genetische Polymorphismen. Bedeutung für Diagnostik und individualisierte Therapie. Frauenarzt 43, 424 (2002)
68. Seeger, H., Mueck, A. O., Lippert, T. H., Estradiol metabolism during oral and transdermal estradiol replacement therapy in the postmenopause. Horm. Metab. Res. 30, 598 (1998)
69. Lippert, T. H., Seeger, H., Mueck, A. O., Beurteilung des Östrogenmetabolismus bei hormonabhängigen Neoplasien unter klinisch-pharmakologischen Aspekten. Arzneim.-Forsch./Drug Res. 49 (II), 649 (1999)
70. Mueck, A. O., Seeger, H., Gräser, T. et al., Effect of postmenopausal HRT and of oral contraceptives on estradiol metabolism. Horm. Metab. Res. 33, 744 (2001)
71. Seeger, H., Mueck, A. O., Lippert, T. H., Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm. Metab. Res. 32, 436 (2000)